Oxford Immunotec Global 10-Q 1 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 25, 2018
Document Information [Line Items]
Entity Registrant Name	Oxford Immunotec Global PLC
Entity Central Index Key	1,586,049
Trading Symbol	oxfd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		25,881,152
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 77,246	$ 90,332
Accounts receivable, net	16,900	16,981
Inventory, net	10,909	10,142
Prepaid expenses and other assets	4,568	3,027
Total current assets	109,623	120,482
Restricted cash, non-current	200	200
Property and equipment, net	9,239	9,067
Goodwill	3,967	3,967
Other intangible assets, net	7,689	7,849
Deferred tax asset	2,915	2,486
Other assets	184	185
Total assets	133,817	144,236
Liabilities and shareholders’ equity
Accounts payable	6,323	6,842
Accrued liabilities	8,564	11,134
Settlement liability	4,581	4,342
Deferred income	32	36
Current portion of loans payable	93	91
Total current liabilities	19,593	22,445
Long-term portion of loans payable	30,020	29,904
Settlement liability	4,106	3,894
Other liabilities	486	364
Total liabilities	54,205	56,607
Commitments and contingencies (Notes 2 and 11)
Shareholders' equity:
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at March 31, 2018 and December 31, 2017, and 25,875,358 and 25,661,634 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	271	269
Additional paid-in capital	296,363	294,613
Accumulated deficit	(211,867)	(201,541)
Accumulated other comprehensive loss	(5,155)	(5,712)
Total shareholders’ equity	79,612	87,629
Total liabilities and shareholders’ equity	$ 133,817	$ 144,236

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - £ / shares	Mar. 31, 2018	Dec. 31, 2017
Common stock, nominal value (in GBP per share)	£ 0.006705	£ 0.006705
Common stock, shares authorized (in shares)	36,183,293	36,183,293
Common stock, shares issued (in shares)	25,875,358	25,661,634
Common stock, shares outstanding (in shares)	25,875,358	25,661,634

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Revenue	$ 21,370	$ 21,505
Cost of revenue:
Cost of goods and services sold	10,590	10,497
Gross profit	10,780	11,008
Operating expenses:
Research and development	3,744	3,805
Sales and marketing	9,405	9,640
General and administrative	6,928	6,876
Change in fair value of contingent purchase price consideration		(2,357)
Settlement expense	207
Total operating expenses	20,284	17,964
Loss from operations	(9,504)	(6,956)
Other expense:
Interest expense, net	(604)	(823)
Foreign exchange losses	(103)	(106)
Other expense	(52)	(140)
Loss before income taxes	(10,263)	(8,025)
Income tax expense	(63)	(47)
Net loss	$ (10,326)	$ (8,072)
Net loss per ordinary share—basic and diluted (in dollars per share)	$ (0.40)	$ (0.36)
Weighted-average shares used to compute net loss per ordinary share—basic and diluted (in shares)	25,718,910	22,533,531
Product [Member]
Revenue:
Revenue	$ 7,935	$ 8,386
Cost of revenue:
Cost of goods and services sold	2,574	3,245
Service [Member]
Revenue:
Revenue	13,435	13,119
Cost of revenue:
Cost of goods and services sold	$ 8,016	$ 7,252

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Other Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net loss	$ (10,326)	$ (8,072)
Other comprehensive income:
Foreign currency translation adjustment, net of taxes	557	219
Other comprehensive income, net of taxes	557	219
Total comprehensive loss	$ (9,769)	$ (7,853)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net loss	$ (10,326)	$ (8,072)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of intangible assets	1,133	1,003
Change in fair value of contingent purchase price consideration		(2,357)
Accretion and amortization of loan fees	140	149
Share-based compensation expense	1,824	1,326
Deferred income taxes	43
Changes in operating assets and liabilities:
Accounts receivable, net	296	(3,573)
Inventory, net	(490)	(806)
Prepaid expenses and other assets	(1,473)	(1,406)
Accounts payable	(624)	522
Accrued liabilities	(2,455)	(1,424)
Net cash used in operating activities	(11,932)	(14,638)
Cash flows from investing activities
Purchases of property and equipment	(1,118)	(1,301)
Net cash used in investing activities	(1,118)	(1,301)
Cash flows from financing activities
Proceeds from exercise of share options	84	59
Payments of tax withheld on vesting of restricted share units	(156)	(186)
Payments on loan	(22)	(21)
Net cash used in financing activities	(94)	(148)
Effect of exchange rate changes on cash and cash equivalents	58	110
Net decrease in cash, cash equivalents, and restricted cash	(13,086)	(15,977)
Cash, cash equivalents, and restricted cash at beginning of period	90,532	59,310
Cash, cash equivalents, and restricted cash at end of period	$ 77,446	$ 43,333

Note 1 - Business and Basis of

Note 1 - Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Description of business Oxford Immunotec Global PLC, or the Company, is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for underserved immune-regulated conditions. The Company’s focus is on four Unaudited i nterim f inancial s tatements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10 10 X. not March 31, 2018, three March 31, 2018 2017, three March 31, 2018 2017. not The consolidated balance sheet presented as of December 31, 2017, 2017 10 February 27, 2018, 2017 10 Cash, cash equivalents, and restricted cash We maintain our available cash balances in cash, money market funds and repurchase agreements primarily invested in U.S. government and agency securities, and bank savings accounts in the United States, United Kingdom, Germany, Japan, China and South Korea. Restricted cash is pledged as collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: (in thousands) March 31, 201 8 December 31, 201 7 Cash and cash equivalents $ 77,246 $ 90,332 Restricted cash, non-current 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 77,446 $ 90,532 Revenues The Company’s revenues include product and service revenues. Product revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. Service revenue from tests performed on samples sent by direct billing customers is recorded based upon contractually established billing rates and recognized upon delivery of test results to the customer. Revenue from tests paid by third 2 As of March 31, 2018, $16.9 three March 31, 2018, no no March 31, 2018. one For the three March 31, 2018, not Revenue expected to be recognized in any future year related to remaining performance obligations is not The remainder of the significant accounting estimates and policies used in preparation of the consolidated financial statements is disclosed in Note 1 2017 10 Recently Adopted Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 2014 09 January 1, 2018, 2014 09 not three March 31, 2018. 2014 09 In August 2016, 2016 15, 2016 15. 2016 15 2016 15 January 1, 2018. 2016 15 not In October 2016, 2016 16, Income Taxes 2016 16. 2016 16 January 1, 2018. 2016 16 not In November 2016, 2016 18, Stat ement of Cash Flows (Topic 230 Rest ricted Cash 2016 18. 2016 18 2016 18 January 1, 2018. 2016 18 not In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 2017 01 January 1, 2018. 2017 01 not In May 2017, 2017 09, Scope of Modification Accounting 2017 09. 2017 09 2017 09 January 1, 2018. 2017 09 not Recently Issued Accounting Pronouncements In February 2016, 2016 02, Leases 2016 02. 2016 02 December 15, 2018. 2016 02 not may In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. 2016 13 not may In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04, not Under the U.S. Jumpstart our Business Startups Act, or the JOBS Act, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Company irrevocably elected not not

Note 2 - Revenue

Note 2 - Revenue	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	2 . Revenue The following table presents the Company’s revenues disaggregated by type: Quarter ended (in thousands, except percentages) 2018 2017 Revenue Product $ 7,935 $ 8,386 Service 13,435 13,119 Total revenue $ 21,370 $ 21,505 The following table presents the Company’s revenues disaggregated by indication: Quarter ended (in thousands, except percentages) 2018 2017 Revenue Tuberculosis $ 18,837 $ 18,542 Tick-borne disease and other 2,533 2,963 Total revenue $ 21,370 $ 21,505 The following table reflects revenue by geography (United States, Europe and rest of world, or Europe and ROW, and Asia): Quarter ended (in thousands, except percentages) 2018 2017 Revenue United States $ 13,393 $ 13,536 Europe and ROW 2,240 1,806 Asia 5,737 6,163 Total revenue $ 21,370 $ 21,505

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3 . Fair value measurement As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three Level 1—Observable Level 2—Observable 1 not Level 3—Unobservable no This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short term nature. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The Company has a term loan outstanding with MidCap Financial Trust, or the MidCap agreement. The amount outstanding on the MidCap agreement is reported at its carrying value in the accompanying balance sheet. The estimated fair value of the MidCap agreement as of March 31, 2018, 2

Note 4 - Accounts Receivable, N

Note 4 - Accounts Receivable, Net	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	4 . Accounts receivable , net Accounts receivable, net, consisted of the following as of: (in thousands) March 31, 201 8 December 31, 201 7 Accounts receivable $ 17,928 $ 17,807 Less allowance for uncollectible accounts receivable (1,028 ) (826 ) Accounts receivable, net $ 16,900 $ 16,981

Note 5 - Inventory, Net

Note 5 - Inventory, Net	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	5 . Inventory , net Inventory, net consisted of the following as of: (in thousands) March 31, 201 8 December 31, 201 7 Raw materials $ 6,783 $ 6,927 Work in progress 330 179 Finished goods 3,796 3,036 Inventory, net $ 10,909 $ 10,142

Note 6 - Goodwill and Acquired

Note 6 - Goodwill and Acquired Intangible Assets	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6 . Goodwill and acquired intangible assets The carrying amount of goodwill reflected in the Company’s condensed consolidated balance sheets was $4.0 March 31, 2018 December 31, 2017 2016 Acquired intangible assets consisted of the following as of March 31, 2018 December 31, 2017: As of March 31, 201 8 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen technology - clinical 15 $ 5,100 $ 595 $ 4,505 Imugen customer relationships 10 1,400 245 1,155 Imugen trademarks / trade names 16 1,140 125 1,015 Immunetics technology - clinical 15 883 86 797 Immunetics customer relationships 11 130 17 113 Immunetics trade name 5 30 9 21 Other 5 - 10 718 635 83 Total $ 9,401 $ 1,712 $ 7,689 As of December 31, 20 17 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen technology - clinical 15 $ 5,100 $ 510 $ 4,590 Imugen customer relationships 10 1,400 210 1,190 Imugen trademarks / trade names 16 1,140 107 1,033 Immunetics technology - clinical 15 883 72 811 Immunetics customer relationships 11 130 14 116 Immunetics trade name 5 30 8 22 Other 5 - 10 692 605 87 Total $ 9,375 $ 1,526 $ 7,849 The weighted average amortization period of our definite-lived intangible assets is 14 $0.7 2018 2020 $0.6 2021 2022.

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7 . Accrued liabilities Accrued liabilities consisted of the following as of: (in thousands) March 31, 201 8 December 31, 201 7 Employee related expenses $ 4,714 $ 6,162 Clinical trials 551 688 Royalties 335 1,419 Other accrued liabilities 2,964 2,865 Total accrued liabilities $ 8,564 $ 11,134

Note 8 - Share Option and Equit

Note 8 - Share Option and Equity Incentive Plan	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8 . Share option and equity incentive plan The impact on the Company’s results of operations from share-based compensation was as follows: Three months ended March 31 , (in thousands) 201 8 201 7 Cost of revenue $ 12 $ 43 Research and development 288 160 Sales and marketing 615 425 General and administrative 909 698 Total share-based compensation $ 1,824 $ 1,326 In November 2013, 2013 2013 2013 2017 During the three March 31, 2018, 684,131 $10.93 $13.24 2013 2013 three March 31, 2018 $6.11 ten During the three March 31, 2018, 117,426 $13.24 2013 40% second 30% third 30% fourth For the three March 31, 2018, $985,000 $839,000, three March 31, 2017, $784,000 $542,000, As of March 31, 2018, $9.8 $4.9 3

Note 9 - Share Capital

Note 9 - Share Capital	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Share capital During the first three 2018, 166,127 47,597

Note 10 - Net Loss Per Share

Note 10 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	10 . Net loss per share The following numbers of outstanding ordinary share options and unvested restricted shares and unvested RSUs were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three months ended March 31 , 201 8 201 7 Options to purchase ordinary shares 508,618 1,186,335 Unvested restricted shares — 63,438 Unvested RSUs 405,527 262,872

Note 11 - Lease Commitments

Note 11 - Lease Commitments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	11 . Lease commitments In March 2018, two two one first two “315 18,000 315 $32,000 $35,000 September 30, 2018. The second March 31, 2023, “320 39,000 320 $67,000 $83,000 two five

Note 12 - Restructuring

Note 12 - Restructuring	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	12 . Restructuring During the third 2017, 15 fourth 2017 $169,000 $13,000 The following table provides a rollforward of the liability balance for this restructuring. Accrued restructuring costs at December 31, 2017 March 31, 2018 (in thousands) Severance Balance at December 31, 2017 $ 74 Payments (44 ) Balance at March 31, 2018 $ 30

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, cash equivalents, and restricted cash We maintain our available cash balances in cash, money market funds and repurchase agreements primarily invested in U.S. government and agency securities, and bank savings accounts in the United States, United Kingdom, Germany, Japan, China and South Korea. Restricted cash is pledged as collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: (in thousands) March 31, 201 8 December 31, 201 7 Cash and cash equivalents $ 77,275 $ 90,332 Restricted cash, non-current 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 77,475 $ 90,532
Revenue from Contract with Customer [Policy Text Block]	Revenues The Company’s revenues include product and service revenues. Product revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. Service revenue from tests performed on samples sent by direct billing customers is recorded based upon contractually established billing rates and recognized upon delivery of test results to the customer. Revenue from tests paid by third 2 As of March 31, 2018, $16.9 three March 31, 2018, no no March 31, 2018. one For the three March 31, 2018, not Revenue expected to be recognized in any future year related to remaining performance obligations is not The remainder of the significant accounting estimates and policies used in preparation of the consolidated financial statements is disclosed in Note 1 2017 10
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 2014 09 January 1, 2018, 2014 09 not three March 31, 2018. 2014 09 In August 2016, 2016 15, 2016 15. 2016 15 2016 15 January 1, 2018. 2016 15 not In October 2016, 2016 16, Income Taxes 2016 16. 2016 16 January 1, 2018. 2016 16 not In November 2016, 2016 18, Stat ement of Cash Flows (Topic 230 Rest ricted Cash 2016 18. 2016 18 2016 18 January 1, 2018. 2016 18 not In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 2017 01 January 1, 2018. 2017 01 not In May 2017, 2017 09, Scope of Modification Accounting 2017 09. 2017 09 2017 09 January 1, 2018. 2017 09 not Recently Issued Accounting Pronouncements In February 2016, 2016 02, Leases 2016 02. 2016 02 December 15, 2018. 2016 02 not may In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. 2016 13 not may In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04, not Under the U.S. Jumpstart our Business Startups Act, or the JOBS Act, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. The Company irrevocably elected not not

Note 1 - Business and Basis o20

Note 1 - Business and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	(in thousands) March 31, 201 8 December 31, 201 7 Cash and cash equivalents $ 77,246 $ 90,332 Restricted cash, non-current 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 77,446 $ 90,532

Note 2 - Revenue (Tables)

Note 2 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Quarter ended (in thousands, except percentages) 2018 2017 Revenue Product $ 7,935 $ 8,386 Service 13,435 13,119 Total revenue $ 21,370 $ 21,505 Quarter ended (in thousands, except percentages) 2018 2017 Revenue Tuberculosis $ 18,837 $ 18,542 Tick-borne disease and other 2,533 2,963 Total revenue $ 21,370 $ 21,505 Quarter ended (in thousands, except percentages) 2018 2017 Revenue United States $ 13,393 $ 13,536 Europe and ROW 2,240 1,806 Asia 5,737 6,163 Total revenue $ 21,370 $ 21,505

Note 4 - Accounts Receivable,22

Note 4 - Accounts Receivable, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	(in thousands) March 31, 201 8 December 31, 201 7 Accounts receivable $ 17,928 $ 17,807 Less allowance for uncollectible accounts receivable (1,028 ) (826 ) Accounts receivable, net $ 16,900 $ 16,981

Note 5 - Inventory, Net (Tables

Note 5 - Inventory, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) March 31, 201 8 December 31, 201 7 Raw materials $ 6,783 $ 6,927 Work in progress 330 179 Finished goods 3,796 3,036 Inventory, net $ 10,909 $ 10,142

Note 6 - Goodwill and Acquire24

Note 6 - Goodwill and Acquired Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	As of March 31, 201 8 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen technology - clinical 15 $ 5,100 $ 595 $ 4,505 Imugen customer relationships 10 1,400 245 1,155 Imugen trademarks / trade names 16 1,140 125 1,015 Immunetics technology - clinical 15 883 86 797 Immunetics customer relationships 11 130 17 113 Immunetics trade name 5 30 9 21 Other 5 - 10 718 635 83 Total $ 9,401 $ 1,712 $ 7,689 As of December 31, 20 17 (in thousands) Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Imugen technology - clinical 15 $ 5,100 $ 510 $ 4,590 Imugen customer relationships 10 1,400 210 1,190 Imugen trademarks / trade names 16 1,140 107 1,033 Immunetics technology - clinical 15 883 72 811 Immunetics customer relationships 11 130 14 116 Immunetics trade name 5 30 8 22 Other 5 - 10 692 605 87 Total $ 9,375 $ 1,526 $ 7,849

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) March 31, 201 8 December 31, 201 7 Employee related expenses $ 4,714 $ 6,162 Clinical trials 551 688 Royalties 335 1,419 Other accrued liabilities 2,964 2,865 Total accrued liabilities $ 8,564 $ 11,134

Note 8 - Share Option and Equ26

Note 8 - Share Option and Equity Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three months ended March 31 , (in thousands) 201 8 201 7 Cost of revenue $ 12 $ 43 Research and development 288 160 Sales and marketing 615 425 General and administrative 909 698 Total share-based compensation $ 1,824 $ 1,326

Note 10 - Net Loss Per Share (T

Note 10 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three months ended March 31 , 201 8 201 7 Options to purchase ordinary shares 508,618 1,186,335 Unvested restricted shares — 63,438 Unvested RSUs 405,527 262,872

Note 12 - Restructuring (Tables

Note 12 - Restructuring (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Restructuring and Related Costs [Table Text Block]	(in thousands) Severance Balance at December 31, 2017 $ 74 Payments (44 ) Balance at March 31, 2018 $ 30

Note 1 - Business and Basis o29

Note 1 - Business and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts Receivable, Net, Current, Total	$ 16,900	$ 16,981

Note 1 - Business and Basis o30

Note 1 - Business and Basis of Presentation - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 77,246	$ 90,332
Restricted cash, non-current	200	200
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 77,446	$ 90,532	$ 43,333	$ 59,310

Note 2 - Revenue - Disaggregati

Note 2 - Revenue - Disaggregation of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 21,370	$ 21,505
UNITED STATES
Revenue	13,393	13,536
Europe and ROW [Member]
Revenue	2,240	1,806
Asia [Member]
Revenue	5,737	6,163
Product [Member]
Revenue	7,935	8,386
Tuberculosis [Member]
Revenue	18,837	18,542
Service [Member]
Revenue	13,435	13,119
Tick-borne Disease and Other [Member]
Revenue	$ 2,533	$ 2,963

Note 4 - Accounts Receivable,32

Note 4 - Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable	$ 17,928	$ 17,807
Less allowance for uncollectible accounts receivable	(1,028)	(826)
Accounts receivable, net	$ 16,900	$ 16,981

Note 5 - Inventory, Net - Summa

Note 5 - Inventory, Net - Summary of Inventory, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Raw materials	$ 6,783	$ 6,927
Work in progress	330	179
Finished goods	3,796	3,036
Inventory, net	$ 10,909	$ 10,142

Note 6 - Goodwill and Acquire34

Note 6 - Goodwill and Acquired Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Goodwill, Ending Balance	$ 3,967	$ 3,967
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 700
Finite-Lived Intangible Assets, Amortization Expense, Year Five	600
Finite-Lived Intangible Assets, Amortization Expense, Year Two	700
Finite-Lived Intangible Assets, Amortization Expense, Year Three	700
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$ 600

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets - Summary of Acquired Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Accumulated Amortization, Finite-Lived Intangible Assets	$ 1,712	$ 1,526
Net Carrying Amount, Finite-Lived Intangible Assets	7,689	7,849
Gross Carrying Amount, Total	9,401	9,375
Net Carrying Amount, Total	$ 7,689	$ 7,849
Technology-Based Intangible Assets [Member] | Imugen [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	15 years	15 years
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 5,100	$ 5,100
Accumulated Amortization, Finite-Lived Intangible Assets	595	510
Net Carrying Amount, Finite-Lived Intangible Assets	$ 4,505	$ 4,590
Technology-Based Intangible Assets [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	15 years	15 years
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 883	$ 883
Accumulated Amortization, Finite-Lived Intangible Assets	86	72
Net Carrying Amount, Finite-Lived Intangible Assets	$ 797	$ 811
Customer Relationships [Member] | Imugen [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	10 years	10 years
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 1,400	$ 1,400
Accumulated Amortization, Finite-Lived Intangible Assets	245	210
Net Carrying Amount, Finite-Lived Intangible Assets	1,155	1,190
Customer Relationships [Member] | Immunetics [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	130	130
Accumulated Amortization, Finite-Lived Intangible Assets	17	14
Net Carrying Amount, Finite-Lived Intangible Assets	$ 113	$ 116
Customer Relationships [Member] | Immunetics [Member] | Minimum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)
Customer Relationships [Member] | Immunetics [Member] | Maximum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)
Trademarks and Trade Names [Member] | Imugen [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	16 years	16 years
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 1,140	$ 1,140
Accumulated Amortization, Finite-Lived Intangible Assets	125	107
Net Carrying Amount, Finite-Lived Intangible Assets	$ 1,015	$ 1,033
Trade Names [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	5 years	5 years
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 30	$ 30
Accumulated Amortization, Finite-Lived Intangible Assets	9	8
Net Carrying Amount, Finite-Lived Intangible Assets	21	22
Other Intangible Assets [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	718	692
Accumulated Amortization, Finite-Lived Intangible Assets	635	605
Net Carrying Amount, Finite-Lived Intangible Assets	$ 83	$ 87
Other Intangible Assets [Member] | Minimum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	5 years	5 years
Other Intangible Assets [Member] | Maximum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	10 years	10 years

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Employee related expenses	$ 4,714	$ 6,162
Clinical trials	551	688
Royalties	335	1,419
Other accrued liabilities	2,964	2,865
Total accrued liabilities	$ 8,564	$ 11,134

Note 8 - Share Option and Equ37

Note 8 - Share Option and Equity Incentive Plan (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Allocated Share-based Compensation Expense, Total	$ 1,824,000	$ 1,326,000
Employee Stock Option [Member]
Allocated Share-based Compensation Expense, Total	985,000	784,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 9,800,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years
Restricted Stock and Restricted Stock Units (RSU's) [Member]
Allocated Share-based Compensation Expense, Total	$ 839,000	$ 542,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 4,900,000
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	684,131
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 10.93
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	13.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.11
2013 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	117,426
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 13.24
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Second Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	40.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Third Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	30.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Fourth Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	30.00%

Note 8 - Share Option and Equ38

Note 8 - Share Option and Equity Incentive Plan - Expense Recognized During the Year Related to Share-based Compensation Transactions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based compensation	$ 1,824	$ 1,326
Cost of Revenue [Member]
Share-based compensation	12	43
Research and Development Expense [Member]
Share-based compensation	288	160
Selling and Marketing Expense [Member]
Share-based compensation	615	425
General and Administrative Expense [Member]
Share-based compensation	$ 909	$ 698

Note 9 - Share Capital (Details

Note 9 - Share Capital (Details Textual)	3 Months Ended
	Mar. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	166,127
Stock Issued During Period, Shares, Restricted Stock Award, Gross	47,597

Note 10 - Net Loss Per Share -

Note 10 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Stock Option [Member]
Antidilutive securities (in shares)	508,618	1,186,335
Restricted Stock [Member]
Antidilutive securities (in shares)		63,438
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	405,527	262,872

Note 11 - Lease Commitments (De

Note 11 - Lease Commitments (Details Textual)	1 Months Ended
	Mar. 31, 2018USD ($)ft²
The 315 Lease [Member]
Area of Real Estate Property | ft²	18,000
The 315 Lease [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense	$ 32,000
The 315 Lease [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense	$ 35,000
The 320 Lease [Member]
Area of Real Estate Property | ft²	39,000
Lessee, Operating Lease, Renewal Term	5 years
The 320 Lease [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense	$ 67,000
The 320 Lease [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense	$ 83,000

Note 12 - Restructuring (Detail

Note 12 - Restructuring (Details Textual) - Plan to Terminate Government Grants [Member]	3 Months Ended
	Dec. 31, 2017USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	15
Research and Development Expense [Member]
Restructuring Charges, Total	$ 169,000
General and Administrative Expense [Member]
Restructuring Charges, Total	$ 13,000

Note 12 - Restructuring - Accru

Note 12 - Restructuring - Accrued Restructuring Costs (Details) - Plan to Terminate Government Grants [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Balance at December 31, 2017	$ 74
Payments	(44)
Balance at March 31, 2018	$ 30